Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis.

Paramarta JE, De Rycke L, Heijda TF, Ambarus CA, Vos K, Dinant HJ, Tak PP, Baeten DL.

Ann Rheum Dis. 2013 Nov;72(11):1793-9. doi: 10.1136/annrheumdis-2012-202245. Epub 2012 Nov 8.

PMID:
23139265
2.

The features of the synovium in early rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria.

van de Sande MG, de Hair MJ, Schuller Y, van de Sande GP, Wijbrandts CA, Dinant HJ, Gerlag DM, Tak PP.

PLoS One. 2012;7(5):e36668. doi: 10.1371/journal.pone.0036668. Epub 2012 May 4.

3.

CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis.

Tran L, Huitema AD, van Rijswijk MH, Dinant HJ, Baars JW, Beijnen JH, Vogel WV.

Hum Antibodies. 2011;20(1-2):29-35. doi: 10.3233/HAB20110239.

PMID:
21558621
4.

The pharmacokinetics of ¹²⁴I-rituximab in patients with rheumatoid arthritis.

Tran L, Vogel WV, Sinaasappel M, Muller S, Baars JW, van Rijswijk M, Dinant HJ, Beijnen JH, Huitema AD.

Hum Antibodies. 2011;20(1-2):7-14. doi: 10.3233/HAB20110237.

PMID:
21558619
5.

Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial.

Vergunst CE, Gerlag DM, Lopatinskaya L, Klareskog L, Smith MD, van den Bosch F, Dinant HJ, Lee Y, Wyant T, Jacobson EW, Baeten D, Tak PP.

Arthritis Rheum. 2008 Jul;58(7):1931-9. doi: 10.1002/art.23591.

6.

Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype.

Thurlings RM, Wijbrandts CA, Mebius RE, Cantaert T, Dinant HJ, van der Pouw-Kraan TC, Verweij CL, Baeten D, Tak PP.

Arthritis Rheum. 2008 Jun;58(6):1582-9. doi: 10.1002/art.23505.

7.

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium.

Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vinkenoog M, Smeets TJ, Dinant H, Vos K, Lems WF, Wolbink GJ, Sijpkens D, Dijkmans BA, Tak PP.

Ann Rheum Dis. 2008 Aug;67(8):1139-44. Epub 2007 Nov 29.

8.

Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation.

Vergunst CE, Gerlag DM, Dinant H, Schulz L, Vinkenoog M, Smeets TJ, Sanders ME, Reedquist KA, Tak PP.

Rheumatology (Oxford). 2007 Dec;46(12):1773-8. Epub 2007 Oct 27.

PMID:
17965442
9.

Joint laxity and the relationship between muscle strength and functional ability in patients with osteoarthritis of the knee.

van der Esch M, Steultjens M, Knol DL, Dinant H, Dekker J.

Arthritis Rheum. 2006 Dec 15;55(6):953-9.

10.

A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.

Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, van den Bosch F, Bresnihan B, Breedveld FC, Dinant HJ, Legay F, Gram H, Loetscher P, Schmouder R, Woodworth T, Tak PP.

Arthritis Rheum. 2006 Aug;54(8):2387-92.

11.

Poor and good health outcomes in rheumatoid arthritis: the role of comorbidity.

Rupp I, Boshuizen HC, Roorda LD, Dinant HJ, Jacobi CE, van den Bos G.

J Rheumatol. 2006 Aug;33(8):1488-95.

PMID:
16832850
12.
13.

Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA.

de Vries PJ, van der Meide WF, Godfried MH, Schallig HD, Dinant HJ, Faber WR.

Trans R Soc Trop Med Hyg. 2006 Dec;100(12):1183-6. Epub 2006 May 6.

PMID:
16678871
14.

Long-term outcome in polymyositis and dermatomyositis.

Bronner IM, van der Meulen MF, de Visser M, Kalmijn S, van Venrooij WJ, Voskuyl AE, Dinant HJ, Linssen WH, Wokke JH, Hoogendijk JE.

Ann Rheum Dis. 2006 Nov;65(11):1456-61. Epub 2006 Apr 10.

15.

Course of patient-reported health outcomes in rheumatoid arthritis: comparison of longitudinal and cross-sectional approaches.

Rupp I, Boshuizen HC, Roorda LD, Dinant HJ, Jacobi CE, van den Bos G.

J Rheumatol. 2006 Feb;33(2):228-33.

PMID:
16465652
16.

Structural joint changes, malalignment, and laxity in osteoarthritis of the knee.

van der Esch M, Steultjens M, Wieringa H, Dinant H, Dekker J.

Scand J Rheumatol. 2005 Jul-Aug;34(4):298-301.

PMID:
16195163
17.

Impact of fatigue on health-related quality of life in rheumatoid arthritis.

Rupp I, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos GA.

Arthritis Rheum. 2004 Aug 15;51(4):578-85.

18.

Burden of caregiving: evidence of objective burden, subjective burden, and quality of life impacts on informal caregivers of patients with rheumatoid arthritis.

Brouwer WB, van Exel NJ, van de Berg B, Dinant HJ, Koopmanschap MA, van den Bos GA.

Arthritis Rheum. 2004 Aug 15;51(4):570-7.

19.

Unmet demands for health care among patients with rheumatoid arthritis: indications for underuse?

Jacobi CE, Rupp I, Boshuizen HC, Triemstra M, Dinant HJ, van den Bos GA.

Arthritis Rheum. 2004 Jun 15;51(3):440-6.

20.

Quality of rheumatoid arthritis care: the patient's perspective.

Jacobi CE, Boshuizen HC, Rupp I, Dinant HJ, van den Bos GA.

Int J Qual Health Care. 2004 Feb;16(1):73-81.

PMID:
15020563
21.

Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis.

Goedkoop AY, de Rie MA, Picavet DI, Kraan MC, Dinant HJ, van Kuijk AW, Tak PP, Bos JD, Teunissen MB.

Arch Dermatol Res. 2004 Apr;295(11):465-73. Epub 2004 Feb 14.

PMID:
14968366
22.

Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission.

Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA.

Arthritis Rheum. 2004 Jan;50(1):36-42.

23.

Comorbidity in patients with rheumatoid arthritis: effect on health-related quality of life.

Rupp I, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos G.

J Rheumatol. 2004 Jan;31(1):58-65.

PMID:
14705219
24.

Polymyositis: an overdiagnosed entity.

van der Meulen MF, Bronner IM, Hoogendijk JE, Burger H, van Venrooij WJ, Voskuyl AE, Dinant HJ, Linssen WH, Wokke JH, de Visser M.

Neurology. 2003 Aug 12;61(3):316-21.

PMID:
12913190
25.

Impact of socioeconomic status on the course of rheumatoid arthritis and on related use of health care services.

Jacobi CE, Mol GD, Boshuizen HC, Rupp I, Dinant HJ, Van Den Bos GA.

Arthritis Rheum. 2003 Aug 15;49(4):567-73.

26.

Dimension-specific burden of caregiving among partners of rheumatoid arthritis patients.

Jacobi CE, van den Berg B, Boshuizen HC, Rupp I, Dinant HJ, van den Bos GA.

Rheumatology (Oxford). 2003 Oct;42(10):1226-33. Epub 2003 Jun 16.

PMID:
12810934
27.

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis.

Kraan MC, van Kuijk AW, Dinant HJ, Goedkoop AY, Smeets TJ, de Rie MA, Dijkmans BA, Vaishnaw AK, Bos JD, Tak PP.

Arthritis Rheum. 2002 Oct;46(10):2776-84.

28.

Selection bias due to non-response in a health survey among patients with rheumatoid arthritis.

Rupp I, Triemstra M, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos GA.

Eur J Public Health. 2002 Jun;12(2):131-5.

PMID:
12073751
29.

Health care utilization among rheumatoid arthritis patients referred to a rheumatology center: unequal needs, unequal care?

Jacobi CE, Triemstra M, Rupp I, Dinant HJ, Van Den Bos GA.

Arthritis Rheum. 2001 Aug;45(4):324-30.

30.

Ferritin and serum transferrin receptor predict iron deficiency in anemic patients with rheumatoid arthritis.

Bultink IE, Lems WF, van de Stadt RJ, Dinant HJ, Leyte A, Park DS, de Koning MH, Dijkmans BA.

Arthritis Rheum. 2001 Apr;44(4):979-81. No abstract available.

31.

Rhemulatologists' performance in dailiy practice.

Gorter S, van der Linden S, Brauer J, van der Heijde D, Houben H, Rethans JJ, Scherpbier A, van der Vleuten C, Boonen A, Dinant H, Thè HG, Griep E, van der Horst-Bruinsma I, Linssen A, van Santen-Hoeufft M, van der Tempel H, Westgeest T.

Arthritis Rheum. 2001 Feb;45(1):16-27.

32.

New therapeutic targets for rheumatoid arthritis.

Dinant HJ, Dijkmans BA.

Pharm World Sci. 1999 Apr;21(2):49-59. Review.

PMID:
10380231
33.

Fibroblast-like synoviocytes from rheumatoid arthritis patients have intrinsic properties of follicular dendritic cells.

Lindhout E, van Eijk M, van Pel M, Lindeman J, Dinant HJ, de Groot C.

J Immunol. 1999 May 15;162(10):5949-56.

34.

[Sore throat in rheumatoid arthritis: 2 patients with cricoarytenoid arthritis].

Jol JA, van Deelen GW, Dinant HJ.

Ned Tijdschr Geneeskd. 1997 Aug 9;141(32):1567-70. Dutch.

PMID:
9543752
35.

Incidence and sources of native and prosthetic joint infection: a community based prospective survey.

Kaandorp CJ, Dinant HJ, van de Laar MA, Moens HJ, Prins AP, Dijkmans BA.

Ann Rheum Dis. 1997 Aug;56(8):470-5.

36.

Cogan's syndrome as an extra-articular manifestation of rheumatoid arthritis.

Dekker JJ, Dinant HJ, Van Soesbergen RM.

Clin Rheumatol. 1996 Jul;15(4):374-7. No abstract available.

PMID:
8853171
37.

The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial.

van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, van der Veen MJ, Haanen HC, Hofman DM, van Albada-Kuipers GA, ter Borg EJ, Brus HL, Dinant HJ, Kruize AA, Schenk Y.

Ann Intern Med. 1996 Apr 15;124(8):699-707.

PMID:
8633829
38.

Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?

van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW.

Ann Rheum Dis. 1996 Apr;55(4):218-23. Erratum in: Ann Rheum Dis 1996 Aug;55(8):563.

39.

Comparison of cystic rheumatoid arthritis and erosive rheumatoid arthritis.

Lycklamaà Nijeholt G, Gubler FM, Scholten RJ, Dinant HJ.

J Rheumatol. 1996 Mar;23(3):447-52.

PMID:
8832980
40.

Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis.

Zonneveld IM, Bakker WK, Dijkstra PF, Bos JD, van Soesbergen RM, Dinant HJ.

Arch Dermatol. 1996 Feb;132(2):184-7.

PMID:
8629827
41.

Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis.

van der Veen MJ, Dekker JJ, Dinant HJ, van Soesbergen RM, Bijlsma JW.

J Rheumatol. 1995 Sep;22(9):1766-8. Review.

PMID:
8523359
42.

The impact of endpoint measures in rheumatoid arthritis clinical trials.

van der Heide A, Jacobs JW, Dinant HJ, Bijlsma JW.

Semin Arthritis Rheum. 1992 Apr;21(5):287-94.

PMID:
1604325
43.

[Fatal liver damage during use of diclofenac].

Snijder RJ, Dinant HJ, Stricker BH.

Ned Tijdschr Geneeskd. 1987 Nov 14;131(46):2088-90. Dutch. No abstract available.

PMID:
3683638
44.

Lack of serologically defined arthritogenic Shigella flexneri cell envelope antigens in post-dysenteric arthritis.

van Bohemen CG, Nabbe AJ, Dinant HJ, Grumet FC, Landheer JE, Zanen HC.

Immunol Lett. 1986 Oct;13(4):197-201.

PMID:
3533766
45.

Lack of correlation between HLA-B27 like antigenic epitopes on Shigella flexneri and the occurrence of reactive arthritis.

van Bohemen CG, Nabbe AJ, Grumet FC, Landheer JE, Dinant HJ, Zanen HC.

Clin Exp Immunol. 1986 Sep;65(3):679-82. No abstract available.

46.

HLA-B27M1M2 and high immune responsiveness to Shigella flexneri in post-dysenteric arthritis.

van Bohemen CG, Nabbe AJ, Landheer JE, Grumet FC, Mazurkiewicz ES, Dinant HJ, Lionarons RJ, van Bodegom PC, Zanen HC.

Immunol Lett. 1986 Aug;13(1-2):71-4.

PMID:
2428743
47.

Susceptibility and HLA-B27 in post-dysenteric arthropathies.

van Bohemen CG, Lionarons RJ, van Bodegom P, Dinant HJ, Landheer JE, Nabbe AJ, Grumet FC, Zanen HC.

Immunology. 1985 Oct;56(2):377-9.

48.

Polyarthritis as the presenting symptom of a malignant fibrous histiocytoma of the heart.

Berkelbach van der Sprenkel JW, Timmermans AJ, Elbers HR, van Herpen G, Dinant HJ.

Arthritis Rheum. 1985 Aug;28(8):944-7. No abstract available.

PMID:
2992529
49.

[5 cases of reactive arthritis following a Shigella flexneri epidemic in the Netherlands].

Lionarons RJ, van Bodegom PC, Landheer JE, van Bohemen CG, Zanen HC, Dinant HJ.

Ned Tijdschr Geneeskd. 1985 May 11;129(19):892-4. Dutch. No abstract available.

PMID:
3892310
50.

Beneficial effect of intravenous cyclophosphamide and oral prednisone on D-penicillamine-associated bronchiolitis obliterans.

van de Laar MA, Westermann CJ, Wagenaar SS, Dinant HJ.

Arthritis Rheum. 1985 Jan;28(1):93-7. No abstract available.

PMID:
3966941

Supplemental Content

Loading ...
Support Center